<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Poststreptococcal glomerulonephritis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Poststreptococcal glomerulonephritis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Poststreptococcal glomerulonephritis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Niaudet, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">F Bruder Stapleton, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 02, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Poststreptococcal glomerulonephritis (PSGN) is caused by prior infection with specific nephritogenic strains of group A beta-hemolytic streptococcus. The clinical presentation of PSGN varies from asymptomatic, microscopic hematuria to the full-blown acute nephritic syndrome, characterized by red to brown urine, proteinuria (which can reach the nephrotic range), edema, hypertension, and acute kidney injury. The prognosis is generally favorable, especially in children, but in some cases, the long-term prognosis is not benign.</p><p>The pathogenesis, clinical manifestations, diagnosis, management, course of disease, and prognosis of PSGN will be reviewed here. Evaluation and causes of other glomerular disease in children are discussed separately. (See  <a class="medical medical_review" href="/d/html/6119.html" rel="external">"Glomerular disease: Evaluation in children"</a> and  <a class="medical medical_review" href="/d/html/6117.html" rel="external">"Overview of the pathogenesis and causes of glomerulonephritis in children"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Although PSGN continues to be the most common cause of acute nephritis in children globally, it primarily occurs in resource-limited countries. Of the estimated 470,000 new annual cases of PSGN worldwide, 97 percent occur in regions of the world with poor socioeconomic status, with an annual incidence that ranges from 9.5 to 28.5 per 100,000 individuals [<a href="#rid1">1-3</a>].</p><p>In more developed and industrialized countries, the incidence has continued to decrease from the 1970s to the 1990s [<a href="#rid2">2,4,5</a>]. Based upon data from the Italian Registry of Renal Biopsies, the estimated annual incidence was 0.3 per 100,000 individuals between 1992 and 1994 [<a href="#rid6">6</a>]. The reasons may include the easier access to the treatment of streptococcal infections and the widespread presence of fluoride in water, which decreases virulence factors of <em>Streptococcus pyogenes</em> [<a href="#rid7">7</a>].</p><p>The risk of PSGN is increased in older patients (greater than 60 years of age) and in children between 5 and 12 years of age [<a href="#rid6">6,8,9</a>]. PSGN is uncommon in children less than three years of age. PSGN is twice as frequent in males as in females [<a href="#rid10">10,11</a>].</p><p>PSGN can present as a sporadic case or during an epidemic of group A streptococcal (GAS) infection (ie, skin and throat infections) [<a href="#rid2">2</a>]. The incidence of clinically detectable PSGN in children infected during a GAS epidemic is approximately 5 to 10 percent with pharyngitis and 25 percent with skin infections [<a href="#rid12">12,13</a>]. For sporadic cases, less than 2 percent of children infected with nephritogenic streptococci strains will develop clinical signs of glomerulonephritis [<a href="#rid14">14</a>]. Therefore, host immune response likely plays a major role in the development of disease.</p><p class="headingAnchor" id="H3"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Although the exact mechanisms of glomerular injury in PSGN have not yet been elucidated, they appear to be caused primarily by an autoimmune response to nephritogenic streptococcal antigens. This autoimmune response leads to immune complex formation and activation of the alternate complement pathway, which result in glomerular inflammation and injury. The immunologic mechanisms involved in the pathogenesis of glomerulonephritis are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/6117.html" rel="external">"Overview of the pathogenesis and causes of glomerulonephritis in children", section on 'Pathogenesis'</a> and  <a class="medical medical_review" href="/d/html/3068.html" rel="external">"Mechanisms of immune injury of the glomerulus"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nephritogenic streptococcal antigens </strong>– There are two leading candidates for the putative streptococcal antigen(s) responsible for PSGN, nephritis-associated plasmin receptor (NAPlr) and streptococcal pyrogenic exotoxin B (SPE B) [<a href="#rid15">15</a>]. NAPlr and SPE B can activate the alternate complement pathway and are capable of inducing chemotactic (monocyte chemoattractant protein 1) and IL-6 moieties in mesangial cells, promoting enhanced expression of adhesion molecules [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>NAPlr</strong> – NAPlr is a glycolytic enzyme which has glyceraldehyde-3-phosphate dehydrogenase (GAPDH) activity [<a href="#rid16">16,17</a>]. NAPlr has a plasmin-like activity which may promote a local inflammatory reaction. An elevated urinary plasmin activity has been observed in patients with acute PSGN [<a href="#rid18">18</a>]. The role of NAPlr in the pathogenesis of PSGN is supported by a study of Japanese patients with PSGN. NAPlr was present in renal biopsy samples obtained within the first 14 days of their disease [<a href="#rid16">16</a>]. Antibodies to NAPlr were also present in the sera of 92 percent of patients with PSGN and 60 percent of patients with uncomplicated GAS infections.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>SPE B</strong> – SPE B is a cationic cysteine proteinase that has been localized to subepithelial deposits [<a href="#rid19">19,20</a>]. In a study that included patients from Latin America and Switzerland, SPE B was found in 12 of 17 biopsies. SPE B deposition colocalized with complement deposition and within the subepithelial electron dense deposits (humps) that are characteristic of PSGN  (<a class="graphic graphic_picture graphicRef76739" href="/d/graphic/76739.html" rel="external">picture 1</a>) [<a href="#rid21">21</a>]. Antibodies to SPE B were also detected in the convalescent sera in all 53 patients who were tested. In contrast, circulating antibodies to NAPlr were found in only 5 of 47 tested sera, and in only one biopsy sample.</p><p></p><p class="bulletIndent2">Although the findings from this study support the role of SPE B as the more likely nephritogenic antigen, an alternate explanation is that separate antigens are responsible for PSGN in different parts of the world and/or in patients with varying genetic backgrounds [<a href="#rid2">2,15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immune complex disease</strong> – PSGN appears to be caused by glomerular immune complex disease induced by specific nephritogenic strains of group A beta-hemolytic streptococcus (GAS). Nephritogenic streptococci strains 12, 4, and 1 are associated with PSGN triggered by throat infections, whereas PSGN secondary to skin infections is associated with strains 49, 42, 2, 57, and 60 [<a href="#rid14">14</a>]. The resulting glomerular immune complex disease triggers complement activation and inflammation. (See  <a class="medical medical_review" href="/d/html/3068.html" rel="external">"Mechanisms of immune injury of the glomerulus"</a> and  <a class="medical medical_review" href="/d/html/6117.html" rel="external">"Overview of the pathogenesis and causes of glomerulonephritis in children", section on 'Pathogenesis'</a>.) </p><p></p><p class="bulletIndent1">The following are proposed mechanisms for the immunologic glomerular injury induced by GAS infection [<a href="#rid15">15</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Deposition of circulating immune complexes with streptococcal antigenic components.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In situ immune complex formation resulting from deposition of streptococcal antigens within the glomerular basement membrane (GBM) and subsequent antibody binding.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In situ glomerular immune complex formation promoted by antibodies to streptococcal antigens that cross-react with glomerular components (molecular mimicry).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Autoantibody formation leading to autoimmune reactivity – A number of autoantibodies have been detected in patients with PSGN [<a href="#rid22">22</a>]: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Anti-factor B antibodies – In one study of 34 children with acute PSGN and low complement levels, anti-factor B antibodies of the immunoglobulin G (IgG) one subclass were detected in 31 patients [<a href="#rid23">23</a>]. Anti-factor B antibodies enhance the activity of the C3 convertase of the alternative pathway; their presence was inversely correlated with the levels of C3. In this study, the presence of anti-factor B antibodies had a sensitivity of 95 percent and a specificity of 82 percent for the diagnosis of PSGN. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Anti-IgG – Anti-IgG reactivity has been reported in patients with acute PSGN. For example, anti-IgG glomerular deposits have been detected in renal biopsy specimens and anti-IgG activity have been found in eluates from the kidney of patient with a fatal case of the disease [<a href="#rid15">15</a>]. It is postulated that modification by streptococcal neuraminidase may modify immunoglobulins, rendering them autoantigenic. This proposed mechanism is supported by the finding of neuraminidase activity and free sialic acid levels in plasma of patients with PSGN [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Anti-DNA antibodies, antineutrophil cytoplasmic antibodies (ANCA), and anticardiolipin antibodies may also be found in some patients [<a href="#rid22">22,25</a>]. The presence of anti-C1q antibodies has been found to be associated with more severe form and delayed resolution of the disease [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Rheumatoid factor (RF) - RF is detected in two-thirds of patients with PSGN.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternate complement pathway activation – </strong>Activation of the alternate complement pathway is a characteristic finding in PSGN. It is likely caused and enhanced by nephritogenic streptococcal antigens and autoantibodies.</p><p></p><p class="headingAnchor" id="H5"><span class="h1">PATHOLOGY</span></p><p class="headingAnchor" id="H6"><span class="h2">Light microscopy</span><span class="headingEndMark"> — </span>Light microscopy shows a diffuse proliferative and exudative glomerulonephritis with prominent endocapillary proliferation and numerous neutrophils  (<a class="graphic graphic_picture graphicRef93170" href="/d/graphic/93170.html" rel="external">picture 2</a> and <a class="graphic graphic_picture graphicRef69657" href="/d/graphic/69657.html" rel="external">picture 3</a>). Trichrome stain may show small subepithelial hump-shaped deposits. The severity of involvement varies and usually correlates with the clinical findings. Patients who are asymptomatic or have mild disease may have biopsies that show little glomerular involvement, whereas patients with diffuse endocapillary proliferative glomerulonephritis are more likely to have full-blown acute nephritic syndrome (ie, red to brown urine, proteinuria, edema, hypertension, and acute renal failure). Crescent formation is uncommon and is associated with a poor prognosis.</p><p class="headingAnchor" id="H7"><span class="h2">Immunofluorescence microscopy</span><span class="headingEndMark"> — </span>Immunofluorescence (IF) microscopy reveals a characteristic pattern of deposits of C3 and immunoglobulin G (IgG) distributed in a diffuse granular pattern within the mesangium and glomerular capillary walls  (<a class="graphic graphic_picture graphicRef56846" href="/d/graphic/56846.html" rel="external">picture 4</a> and <a class="graphic graphic_picture graphicRef93170" href="/d/graphic/93170.html" rel="external">picture 2</a>) [<a href="#rid27">27</a>].The granular pattern of C3 deposition in the capillary walls (garland-type deposits) gives a "starry sky" pattern [<a href="#rid28">28</a>]. Other immune reactants (eg, immunoglobulin M [IgM], immunoglobulin A [IgA], fibrin, and other complement components) may also be detected.</p><p class="headingAnchor" id="H8"><span class="h2">Electron microscopy</span><span class="headingEndMark"> — </span>The most characteristic feature detected by electron microscopy (EM) are the dome-shaped subepithelial electron-dense deposits that are referred to as humps  (<a class="graphic graphic_picture graphicRef76739" href="/d/graphic/76739.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef93170" href="/d/graphic/93170.html" rel="external">picture 2</a>) [<a href="#rid29">29</a>]. These deposits along with subendothelial deposits are immune complexes and correspond to the deposits of IgG and C3 found on IF [<a href="#rid27">27</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Subendothelial immune deposits and subsequent complement activation are responsible for the local influx of inflammatory cells, leading to a proliferative glomerulonephritis, an active urine sediment, and a variable decline in glomerular filtration rate (GFR) [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subepithelial "humps" are responsible for epithelial cell damage and proteinuria, similar to that seen in membranous nephropathy [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology"</a>.)</p><p></p><p>It has been proposed that the clinical course of PSGN is related to the different rates of clearance of immune complexes at these two sites. (See <a class="local">'Correlation with histologic recovery'</a> below.)</p><p class="headingAnchor" id="H9"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H2651936502"><span class="h2">Clinical presentation</span><span class="headingEndMark"> — </span>The clinical presentation varies from asymptomatic, microscopic hematuria to the full-blown acute nephritic syndrome, characterized by red to brown urine, proteinuria (which can reach the nephrotic range), edema, hypertension, and an elevation in serum creatinine [<a href="#rid10">10,32,33</a>]. However, most children are asymptomatic, as illustrated by a study of 248 children with group A streptococcal (GAS) infection, of whom 20 developed urinary abnormalities and a transient decrease in serum complement activity, but only one of whom was clinically symptomatic [<a href="#rid33">33</a>]. A course of rapidly progressive ("crescentic") glomerulonephritis occurs in less than 0.5 percent of cases [<a href="#rid34">34</a>].</p><p>There is usually an antecedent history of a GAS skin or throat infection [<a href="#rid8">8,32,33</a>]. The latent period between GAS infection and PSGN is dependent upon the site of infection: between one and three weeks following GAS pharyngitis and between three and six weeks following GAS skin infection [<a href="#rid35">35</a>].</p><p>The following symptoms are the most common presenting signs in children [<a href="#rid10">10,32,33,36</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Edema − Generalized edema is present in approximately two-thirds of patients due to sodium and water retention. In severe cases, fluid overload leads to respiratory distress due to pulmonary edema.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gross hematuria − Gross hematuria is present in approximately 30 to 50 percent of patients. The urine looks smoky, and tea or cola colored.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension − Hypertension is present in 50 to 90 percent of patients and varies from mild to severe. It is primarily caused by salt and fluid retention. Hypertensive encephalopathy is an uncommon but serious complication. Magnetic resonance imaging (MRI) may show posterior reversible leukoencephalopathy [<a href="#rid37">37,38</a>]. These patients require emergent intervention. (See  <a class="medical medical_review" href="/d/html/6468.html" rel="external">"Initial management of hypertensive emergencies and urgencies in children"</a> and  <a class="medical medical_review" href="/d/html/6438.html" rel="external">"Approach to hypertensive emergencies and urgencies in children", section on 'Hypertensive emergency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subclinical cases of PSGN are primarily characterized by microscopic hematuria [<a href="#rid33">33,39,40</a>]. Such patients were often detected during epidemics.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some patients present with hypertensive encephalopathy or acute pulmonary edema with minor urine abnormalities [<a href="#rid41">41</a>].</p><p></p><p class="headingAnchor" id="H10"><span class="h2">Laboratory findings</span></p><p class="headingAnchor" id="H4218446663"><span class="h3">Renal function</span><span class="headingEndMark"> — </span>PSGN is associated with a variable decline in glomerular filtration rate (GFR) that is detected by a rise in serum creatinine. Acute kidney injury develops in approximately 20 percent of cases [<a href="#rid42">42</a>], but uncommonly requires dialysis (See  <a class="medical medical_review" href="/d/html/6126.html" rel="external">"Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis"</a>.)</p><p class="headingAnchor" id="H11"><span class="h3">Urinalysis and urinary protein excretion</span><span class="headingEndMark"> — </span>The urinalysis in patients with PSGN reveals hematuria (some of the red cells are typically dysmorphic) with or without red blood cell casts  (<a class="graphic graphic_picture graphicRef130438" href="/d/graphic/130438.html" rel="external">picture 5</a> and <a class="graphic graphic_picture graphicRef62064" href="/d/graphic/62064.html" rel="external">picture 6</a> and <a class="graphic graphic_picture graphicRef55778" href="/d/graphic/55778.html" rel="external">picture 7</a>), varying degrees of proteinuria, and often pyuria. Nephrotic range proteinuria (defined as ≥1000 mg/m<sup>2</sup> per day or 40 mg/m<sup>2</sup> per hour) is uncommon and occurs in approximately 5 percent of cases at presentation [<a href="#rid43">43</a>]. The urinalysis should be performed on a freshly voided specimen.</p><p class="headingAnchor" id="H12"><span class="h3">Complement</span><span class="headingEndMark"> — </span>In approximately 90 percent of patients, C3 and CH50 (total complement activity) are significantly depressed in the first two weeks of the disease course [<a href="#rid44">44,45</a>]. As C4 is usually within normal values, low C3 is the result of the activation of the alternative pathway due to the presence of factor B autoantibodies [<a href="#rid23">23</a>]. C4 and C2 levels may be low in some patients, which suggests activation of both classical and alternative pathways [<a href="#rid46">46</a>]. The C3 and CH50 return to normal within four to eight weeks after presentation.</p><p class="headingAnchor" id="H13"><span class="h3">Culture</span><span class="headingEndMark"> — </span>Because PSGN presents weeks after an antecedent GAS infection, only approximately 25 percent of patients will have either a positive throat or skin culture [<a href="#rid8">8</a>]. In patients with impetigo, there is an increased likelihood of obtaining a positive skin culture [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H14"><span class="h3">Serology</span><span class="headingEndMark"> — </span>Elevated titers of antibodies to extracellular streptococcal products are evidence of a recent GAS infection. (See  <a class="medical medical_review" href="/d/html/3167.html" rel="external">"Group A streptococcus: Virulence factors and pathogenic mechanisms", section on 'Toxins and other secreted virulence factors'</a>.)</p><p>The best markers for PSGN are serum antibody levels to NAPlr or SPEB/zSPEB, but these tests are rarely available [<a href="#rid47">47,48</a>].</p><p>The streptozyme test, which measures five different streptococcal antibodies, is positive in more than 95 percent of patients due to pharyngitis and approximately 80 percent of those with skin infections [<a href="#rid41">41,49,50</a>]. It includes the following antibodies:</p><p class="bulletIndent1"><span class="glyph">●</span>Anti-streptolysin (ASO)</p><p class="bulletIndent1"><span class="glyph">●</span>Anti-hyaluronidase (AHase)</p><p class="bulletIndent1"><span class="glyph">●</span>Anti-streptokinase (ASKase)</p><p class="bulletIndent1"><span class="glyph">●</span>Anti-nicotinamide-adenine dinucleotidase (anti-NAD)</p><p class="bulletIndent1"><span class="glyph">●</span>Anti-DNase B antibodies</p><p></p><p>These antibodies can also be measured individually. After a pharyngeal infection, the ASO, anti-DNase B, anti-NAD, and AHase titers are commonly elevated. In comparison, only the anti-DNase B and AHase titers are typically increased after a skin infection.</p><p>If only the ASO titer is used to screen for GAS infection, it may be falsely low or negative in patients with skin infections [<a href="#rid49">49</a>]. It remains a useful test in patients with PSGN due to GAS pharyngitis but in some cases, the rise in ASO titer may be blunted in patients with pharyngitis who have received antimicrobial therapy. (See  <a class="medical medical_review" href="/d/html/3167.html" rel="external">"Group A streptococcus: Virulence factors and pathogenic mechanisms", section on 'Streptolysin O'</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>PSGN is usually diagnosed based upon clinical findings of acute nephritis and demonstration of a recent group A beta-hemolytic streptococcal (GAS) infection.</p><p class="bulletIndent1"><span class="glyph">●</span>The clinical findings of acute nephritis include hematuria with or without red blood cell casts, variable degrees of proteinuria, edema, oliguria, and hypertension. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Documentation of a recent GAS infection includes either a positive throat or skin culture or serologic tests (eg, anti-streptolysin [ASO] or streptozyme test). (See <a class="local">'Serology'</a> above.)</p><p></p><p>Although a low C3 and/or CH50 (total complement) level are consistent with a diagnosis of PSGN, these complement components may also be decreased in other forms of glomerulonephritis, including membranoproliferative glomerulonephritis. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>A delay in the diagnosis of PSGN is more common in children who do not have a history of an antecedent GAS infection and have microscopic hematuria. This was illustrated in a case series of 57 children with PSGN who had a delay in diagnosis of greater than 24 hours [<a href="#rid51">51</a>]. In most of the patients, presenting findings were due to volume overload and included hypertension, edema, and pulmonary edema. The authors concluded that acute nephritis needs to be considered in any child who presents with symptoms secondary to volume overload and that a urinalysis should be obtained as an initial diagnostic test.</p><p>Renal biopsy is not performed in most patients to confirm the diagnosis of PSGN, since the resolution of PSGN typically begins within one week of presentation. (See <a class="local">'Renal biopsy'</a> below and <a class="local">'Indications for renal biopsy'</a> below.)</p><p class="headingAnchor" id="H17"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of PSGN is generally straightforward in patients once the diagnosis of acute nephritis is made, there is documentation of a recent group A beta-hemolytic streptococcal (GAS) infection, and the nephritis begins to resolve within one or two weeks of presentation. However, if there is progressive disease beyond two weeks, persistent hematuria or hypertension beyond four or six weeks, or there is not adequate documentation of an antecedent GAS infection, the following causes of glomerulonephritis (GN) need to be considered. A renal biopsy may be needed to differentiate PSGN from these other disorders:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>C3 glomerulopathy</strong> – The presentation of C3 glomerulopathy may be indistinguishable initially from PSGN. It typically presents with hematuria, hypertension, proteinuria, and hypocomplementemia, which may follow an upper respiratory infection in some patients. However, patients with C3 glomerulopathy continue to have persistent urinary abnormalities and hypocomplementemia beyond four to six weeks and possibly a further elevation in serum creatinine. In contrast, patients with PSGN typically have resolution of their disease and a return of normal C3 and CH50 levels. (See  <a class="medical medical_review" href="/d/html/3090.html" rel="external">"C3 glomerulopathies: Dense deposit disease and C3 glomerulonephritis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IgA nephropathy</strong> − Patients with IgA nephropathy often present after an upper respiratory infection, similar to the presentation of patients with PSGN. Potential distinguishing features from PSGN include a shorter time between the antecedent illness and hematuria (less than 5 versus more than 10 days in PSGN) and a history of prior episodes of gross hematuria since recurrence is rare in PSGN. (See  <a class="medical medical_review" href="/d/html/3112.html" rel="external">"IgA nephropathy: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/3041.html" rel="external">"Glomerular disease: Evaluation and differential diagnosis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary causes of glomerulonephritis</strong> − Lupus nephritis and IgA vasculitis (IgAV; Henoch-Schönlein purpura [HSP]) nephritis share similar features to PSGN. However, extrarenal manifestations of the underlying systemic diseases and laboratory testing should differentiate them from PSGN. Measurement of serum complement may also be helpful. Hypocomplementemia is not observed in patients with IgAV (HSP) and the hypocomplementemia that occurs in lupus nephritis is, as mentioned above, associated with reductions in both C3 and C4, whereas C4 levels are usually normal in PSGN. (See  <a class="medical medical_review" href="/d/html/3107.html" rel="external">"IgA vasculitis (Henoch-Schönlein purpura): Kidney manifestations"</a> and  <a class="medical medical_review" href="/d/html/3056.html" rel="external">"Lupus nephritis: Diagnosis and classification"</a> and <a class="local">'Complement'</a> above.)</p><p></p><p class="bulletIndent1">Both hepatitis B and endocarditis-associated glomerulonephritis share common features with PSGN and also will present with reductions in C3 and C4. (See  <a class="medical medical_review" href="/d/html/3119.html" rel="external">"Kidney disease associated with hepatitis B virus infection"</a> and  <a class="medical medical_review" href="/d/html/3054.html" rel="external">"Kidney disease in the setting of infective endocarditis or an infected ventriculoatrial shunt"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postinfectious GN due to other microbial agents</strong> − Acute nephritis due to viral and other bacterial agents has been reported  (<a class="graphic graphic_table graphicRef76710" href="/d/graphic/76710.html" rel="external">table 1</a>). The clinical presentation is similar to that of PSGN except that there is no documentation of an antecedent GAS infection.</p><p></p><p class="headingAnchor" id="H18"><span class="h1">ACUTE MANAGEMENT</span></p><p class="headingAnchor" id="H4156852701"><span class="h2">Antibiotic therapy</span><span class="headingEndMark"> — </span>If the streptococcal infection is still present at the time of diagnosis, penicillin therapy should be given (or in allergic patients, <a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">erythromycin</a>). Although uncertain, early treatment of streptococcal infection has been reported to prevent or reduce the severity of glomerulonephritis [<a href="#rid52">52,53</a>]. (See  <a class="medical medical_review" href="/d/html/8049.html" rel="external">"Treatment and prevention of streptococcal pharyngitis in adults and children"</a> and  <a class="medical medical_review" href="/d/html/106447.html" rel="external">"Skin and soft tissue infections in neonates: Evaluation and management"</a>.)</p><p>Preventive antibiotic treatment may be indicated in case of an epidemic situation or for household members of index cases [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H530228043"><span class="h2">Supportive care</span><span class="headingEndMark"> — </span>There is no specific therapy for PSGN. Management is supportive and is focused on treating the clinical manifestations of the disease, particularly complications due to volume overload. These include hypertension and, less commonly, pulmonary edema. General measures include sodium and water restriction and loop diuretics. (See  <a class="medical medical_review" href="/d/html/6104.html" rel="external">"Evaluation and management of edema in children", section on 'General supportive care'</a>.)</p><p>Loop diuretics generally provide a prompt diuresis with reduction of blood pressure and edema. In our practice, intravenous <a class="drug drug_general" data-topicid="8482" href="/d/drug information/8482.html" rel="external">furosemide</a> is given at an initial dose of 1 mg/kg (maximum 40 mg).</p><p>Infrequently, patients have hypertensive encephalopathy due to severe hypertension. These patients should be treated emergently to reduce their blood pressure. Oral <a class="drug drug_general" data-topicid="9700" href="/d/drug information/9700.html" rel="external">nifedipine</a> or parenteral <a class="drug drug_general" data-topicid="9697" href="/d/drug information/9697.html" rel="external">nicardipine</a> are effective, while angiotensin-converting enzyme (ACE) inhibitors should be used with caution due to the risk of hyperkalemia. (See  <a class="medical medical_review" href="/d/html/6468.html" rel="external">"Initial management of hypertensive emergencies and urgencies in children", section on 'Initial management'</a>.)</p><p>Patients with PSGN have variable reductions in renal function, and some patients require dialysis during the acute episode. The management of acute kidney injury in children, including indications for dialysis, is discussed separately. (See  <a class="medical medical_review" href="/d/html/6090.html" rel="external">"Prevention and management of acute kidney injury (acute renal failure) in children", section on 'Management of acute kidney injury'</a>.)</p><p>Patients with evidence of recurrent group A streptococcal (GAS) infection should be given a course of antibiotic therapy. (See  <a class="medical medical_review" href="/d/html/8049.html" rel="external">"Treatment and prevention of streptococcal pharyngitis in adults and children", section on 'Persistent or recurrent symptoms'</a> and  <a class="medical medical_review" href="/d/html/7655.html" rel="external">"Impetigo", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H1309749816"><span class="h2">Indications for referral</span><span class="headingEndMark"> — </span>Indications for referral to a center with expertise in treating children with significant renal disease (eg, provide dialysis and perform renal biopsy) include:</p><p class="bulletIndent1"><span class="glyph">●</span>Fluid overload that is unresponsive or slow to respond to supportive measures (fluid restriction and diuretic therapy)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Refractory hypertension</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of serious renal function compromise (elevated and rising serum creatinine)</p><p></p><p class="headingAnchor" id="H1038853483"><span class="h3">Dialysis</span><span class="headingEndMark"> — </span>For patients with serious renal impairment, indications for dialysis include (see  <a class="medical medical_review" href="/d/html/6090.html" rel="external">"Prevention and management of acute kidney injury (acute renal failure) in children", section on 'Management of acute kidney injury'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Life-threatening fluid overload (pulmonary edema, heart failure, and hypertension) that is refractory to medical therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperkalemia (serum or plasma potassium &gt;6.5 mEq/L) unresponsive to medical therapy (see  <a class="medical medical_review" href="/d/html/85908.html" rel="external">"Management of hyperkalemia in children", section on 'Therapies removing potassium from the body'</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Uremia defined as a BUN between 89 to 100 mg/dL.</p><p></p><p class="headingAnchor" id="H2318299103"><span class="h3">Renal biopsy</span><span class="headingEndMark"> — </span>In the acute setting, because it is unusual for patients with PSGN to require dialysis, a renal biopsy is performed in patients with significant renal impairment who require or are progressing towards dialysis treatment to confirm the diagnosis of PSGN. A renal biopsy is also indicated in cases of normal levels of C3 at presentation or when C3 remains low after one month.</p><p>Patients with more than 30 percent crescents on renal biopsy are often treated with <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> pulses, although there is no evidence that aggressive immunosuppressive therapy has a beneficial effect in patients with rapidly progressive crescentic disease [<a href="#rid54">54</a>]. (See  <a class="medical medical_review" href="/d/html/3113.html" rel="external">"Overview of the classification and treatment of rapidly progressive (crescentic) glomerulonephritis", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">COURSE AND FOLLOW-UP</span><span class="headingEndMark"> — </span>Resolution of the clinical manifestations of PSGN is generally quite rapid, assuming concurrent resolution of the infection. A diuresis typically begins within one week, and the serum creatinine returns to the previous baseline by three to four weeks [<a href="#rid10">10,55</a>].</p><p>Urinary abnormalities disappear at differing rates. Hematuria usually resolves within three to six months. Proteinuria usually disappears earlier than microscopic hematuria. </p><p>In severe cases with nephrotic range proteinuria (defined as ≥1000 mg/m<sup>2</sup> per day or 40 mg/m<sup>2</sup> per hour), this degree of proteinuria may persist for six months or more, long after the hematuria has disappeared [<a href="#rid28">28,56</a>]. </p><p class="headingAnchor" id="H1220324165"><span class="h2">Indications for renal biopsy</span><span class="headingEndMark"> — </span>A biopsy is usually performed in patients in whom other glomerular disorders are being considered because their disease courses deviate from that of PSGN or they present late without a clear history of prior streptococcal infection. (See <a class="local">'Differential diagnosis'</a> above and <a class="local">'Course and follow-up'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>Persistently low C3 levels beyond six weeks are suggestive of a diagnosis of C3 glomerulopathy as C3 levels typically normalize in patients with PSGN by this timeframe. (See  <a class="medical medical_review" href="/d/html/3055.html" rel="external">"Membranoproliferative glomerulonephritis: Classification, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/3090.html" rel="external">"C3 glomerulopathies: Dense deposit disease and C3 glomerulonephritis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent episodes of hematuria are suggestive of IgA nephropathy and are rare in PSGN.</p><p></p><p>A persistent or progressive increase in serum creatinine is uncharacteristic of PSGN, but there are occasional patients whose renal function does not fully recover.</p><p class="headingAnchor" id="H20"><span class="h2">Correlation with histologic recovery</span><span class="headingEndMark"> — </span>The histologic course parallels the improvements seen clinically. There is a marked reduction in the number of inflammatory cells in the glomeruli and the number of immune deposits seen on electron microscopy as the clinical manifestations resolve [<a href="#rid31">31,57</a>].</p><p>The prolonged resolution of proteinuria compared with the more rapid return of renal function and remission of hematuria probably reflects the slower rate of clearance of subepithelial compared with subendothelial immune complexes.</p><p class="bulletIndent1"><span class="glyph">●</span>Subendothelial immune complexes are rapidly cleared by the inflammatory cells from the systemic circulation, thereby accounting for the resolution of hematuria and renal insufficiency [<a href="#rid31">31</a>]. They may not be seen on renal biopsy unless performed early in the course.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subepithelial deposits are separated from circulating inflammatory cells by the glomerular basement membrane, thereby limiting their rate of removal [<a href="#rid31">31,57</a>]. In general, the degree of proteinuria correlates with the number of subepithelial deposits [<a href="#rid28">28</a>].</p><p></p><p class="headingAnchor" id="H21"><span class="h2">Recurrence</span><span class="headingEndMark"> — </span>Recurrent episodes of PSGN are rare [<a href="#rid32">32,34,58,59</a>]. This may be due to the long-term persistence of antibodies to nephritis-associated streptococcal antigens [<a href="#rid60">60</a>]. (See <a class="local">'Pathogenesis'</a> above.)</p><p class="headingAnchor" id="H22"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Most patients, particularly children, have an excellent outcome [<a href="#rid2">2,10,30,61,62</a>]. This is true even in patients who present with acute renal failure and may have crescents on the initial renal biopsy [<a href="#rid54">54,55,63</a>]. A review of three case series of 229 children with PSGN found that approximately 20 percent had an abnormal urinalysis (proteinuria and/or hematuria), but almost all (92 to 99 percent) had normal or only modestly reduced renal function 5 to 18 years after presentation [<a href="#rid2">2</a>].</p><p>However, the long-term prognosis of PSGN is not always benign [<a href="#rid3">3</a>]. Some patients, particularly adults, develop hypertension, recurrent proteinuria (with a relatively normal urine sediment), and renal insufficiency as long as 10 to 40 years after the initial illness [<a href="#rid9">9,64-66</a>]. A study from Australia involved 200 Aboriginal children who had had at least one episode of PSGN, with 27 having had multiple episodes. In this cohort, all PSGN episodes were associated with group A streptococcal (GAS) skin infections, often related to scabies. Five years or later, these patients were three to four times more likely to have significant albuminuria compared with people without a previous history of PSGN [<a href="#rid67">67</a>].</p><p>These late renal complications are associated with glomerulosclerosis on renal biopsy, which is thought to be hemodynamically mediated. According to this hypothesis, some glomeruli are irreversibly damaged during the acute episode and compensatory hyperfiltration in the remaining glomeruli maintains a relatively normal glomerular filtration rate (GFR). However, this adaptive response results in increases in glomerular pressure and size, both of which may then contribute to nonimmunologic glomerular injury and progressive renal dysfunction. It is possible that, in those patients who develop glomerulosclerosis, renal damage can be prevented or ameliorated by antihypertensive therapy (preferentially with an angiotensin-converting enzyme [ACE] inhibitor). (See  <a class="medical medical_review" href="/d/html/7181.html" rel="external">"Secondary factors and progression of chronic kidney disease"</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Poststreptococcal glomerular nephritis (PSGN) is the most common cause of acute nephritis worldwide. It primarily occurs in resource-limited countries. The risk of PSGN is greatest in children between 5 and 12 years of age, and in older adults greater than 60 years of age. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – PSGN is caused by glomerular immune complex disease induced by specific nephritogenic strains of group A beta-hemolytic streptococcus (GAS). The two leading candidates for nephritogenic antigens are nephritis-associated plasmin receptor and streptococcal pyrogenic exotoxin B. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microscopic findings</strong> – The characteristic pathologic features of PSGN are demonstrated by electron microscopy (dome-shaped subepithelial deposits) and immunofluorescence (deposition of immunoglobulin G [IgG] and C3 in a diffuse granular pattern in the mesangium and glomerular capillary walls)  (<a class="graphic graphic_picture graphicRef76739" href="/d/graphic/76739.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef56846" href="/d/graphic/56846.html" rel="external">picture 4</a> and <a class="graphic graphic_picture graphicRef51022" href="/d/graphic/51022.html" rel="external">picture 8</a> and <a class="graphic graphic_picture graphicRef93170" href="/d/graphic/93170.html" rel="external">picture 2</a>). The light microscopic findings of cellular infiltration and glomerular proliferation are nonspecific  (<a class="graphic graphic_picture graphicRef69657" href="/d/graphic/69657.html" rel="external">picture 3</a>). (See <a class="local">'Pathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – The most common clinical findings include edema, gross hematuria, and hypertension. However, the presentation of PSGN varies from asymptomatic, microscopic hematuria to the full-blown acute nephritic syndrome (gross hematuria, proteinuria, edema, hypertension, and acute kidney injury). (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory findings</strong> – Laboratory findings include an abnormal urinalysis (dysmorphic red blood cells, varying degrees of proteinuria, red blood cell casts, and pyuria), positive serology for antibodies to streptococcal antigens, and hypocomplementemia. (See <a class="local">'Laboratory findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – PSGN is typically diagnosed based upon the findings of acute nephritis (eg, hematuria with or without red blood cell casts and proteinuria) and demonstration of a recent GAS infection (eg, positive throat or skin culture or serologic tests [anti-streptolysin [ASO] or streptozyme test]). (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – Although several glomerulonephritides (eg, C3 glomerulonephritis and immunoglobulin A [IgA] nephropathy) may have similar presentations to PSGN, specific clinical differences usually can differentiate among them. In cases where the diagnosis is uncertain, a renal biopsy may be needed to identify the specific renal disease. (See <a class="local">'Differential diagnosis'</a> above and <a class="local">'Indications for renal biopsy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – There is no specific therapy to treat PSGN. Management is supportive and is focused upon treating the volume overload that causes the clinical complications of PSGN. These general measures include sodium and water restriction, and diuretic therapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antibiotic therapy</strong> – Antibiotic therapy is given to those who have still have a streptococcal infection at the time of diagnosis. (See <a class="local">'Antibiotic therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dialysis</strong> – In patients with acute renal failure, dialysis may be required. The indications for dialysis are discussed separately. (See  <a class="medical medical_review" href="/d/html/6090.html" rel="external">"Prevention and management of acute kidney injury (acute renal failure) in children", section on 'Management of acute kidney injury'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management of hypertension</strong> – In patients with hypertension, we suggest administration of <a class="drug drug_general" data-topicid="8482" href="/d/drug information/8482.html" rel="external">furosemide</a> to provide a prompt diuresis and a reduction of blood pressure (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Infrequently, patients may have hypertensive encephalopathy due to severe hypertension and require emergent therapy to reduce their blood pressure. (See <a class="local">'Acute management'</a> above and  <a class="medical medical_review" href="/d/html/6468.html" rel="external">"Initial management of hypertensive emergencies and urgencies in children", section on 'Initial management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical course and prognosis</strong> – Most patients, particularly children, have complete clinical recovery, and resolution of their disease process begins within the first two weeks. However, there is a small subset of patients who have late renal complications (ie, hypertension, increasing proteinuria, and renal insufficiency). (See <a class="local">'Course and follow-up'</a> above and <a class="local">'Prognosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005; 5:685.</a></li><li><a class="nounderline abstract_t">Rodriguez-Iturbe B, Musser JM. The current state of poststreptococcal glomerulonephritis. J Am Soc Nephrol 2008; 19:1855.</a></li><li><a class="nounderline abstract_t">Kanjanabuch T, Kittikowit W, Eiam-Ong S. An update on acute postinfectious glomerulonephritis worldwide. Nat Rev Nephrol 2009; 5:259.</a></li><li><a class="nounderline abstract_t">Zhang Y, Shen Y, Feld LG, Stapleton FB. Changing pattern of glomerular disease at Beijing Children's Hospital. Clin Pediatr (Phila) 1994; 33:542.</a></li><li><a class="nounderline abstract_t">Roy S 3rd, Stapleton FB. Changing perspectives in children hospitalized with poststreptococcal acute glomerulonephritis. Pediatr Nephrol 1990; 4:585.</a></li><li><a class="nounderline abstract_t">Coppo R, Gianoglio B, Porcellini MG, Maringhini S. Frequency of renal diseases and clinical indications for renal biopsy in children (report of the Italian National Registry of Renal Biopsies in Children). Group of Renal Immunopathology of the Italian Society of Pediatric Nephrology and Group of Renal Immunopathology of the Italian Society of Nephrology. Nephrol Dial Transplant 1998; 13:293.</a></li><li><a class="nounderline abstract_t">Thongboonkerd V, Luengpailin J, Cao J, et al. Fluoride exposure attenuates expression of Streptococcus pyogenes virulence factors. J Biol Chem 2002; 277:16599.</a></li><li><a class="nounderline abstract_t">Blyth CC, Robertson PW, Rosenberg AR. Post-streptococcal glomerulonephritis in Sydney: a 16-year retrospective review. J Paediatr Child Health 2007; 43:446.</a></li><li><a class="nounderline abstract_t">Lien JW, Mathew TH, Meadows R. Acute post-streptococcal glomerulonephritis in adults: a long-term study. Q J Med 1979; 48:99.</a></li><li><a class="nounderline abstract_t">Lewy JE, Salinas-Madrigal L, Herdson PB, et al. Clinico-pathologic correlations in acute poststreptococcal glomerulonephritis. A correlation between renal functions, morphologic damage and clinical course of 46 children with acute poststreptococcal glomerulonephritis. Medicine (Baltimore) 1971; 50:453.</a></li><li><a class="nounderline abstract_t">Rodriguez-Iturbe B. Postinfectious glomerulonephritis. Am J Kidney Dis 2000; 35:XLVI.</a></li><li><a class="nounderline abstract_t">STETSON CA, RAMMELKAMP CH Jr, KRAUSE RM, et al. Epidemic acute nephritis: studies on etiology, natural history and prevention. Medicine (Baltimore) 1955; 34:431.</a></li><li><a class="nounderline abstract_t">Anthony BF, Kaplan EL, Wannamaker LW, et al. Attack rates of acute nephritis after type 49 streptococcal infection of the skin and of the respiratory tract. J Clin Invest 1969; 48:1697.</a></li><li><a class="nounderline abstract_t">Satoskar AA, Parikh SV, Nadasdy T. Epidemiology, pathogenesis, treatment and outcomes of infection-associated glomerulonephritis. Nat Rev Nephrol 2020; 16:32.</a></li><li><a class="nounderline abstract_t">Rodríguez-Iturbe B, Batsford S. Pathogenesis of poststreptococcal glomerulonephritis a century after Clemens von Pirquet. Kidney Int 2007; 71:1094.</a></li><li><a class="nounderline abstract_t">Yoshizawa N, Yamakami K, Fujino M, et al. Nephritis-associated plasmin receptor and acute poststreptococcal glomerulonephritis: characterization of the antigen and associated immune response. J Am Soc Nephrol 2004; 15:1785.</a></li><li><a class="nounderline abstract_t">Oda T, Yoshizawa N, Yamakami K, et al. Localization of nephritis-associated plasmin receptor in acute poststreptococcal glomerulonephritis. Hum Pathol 2010; 41:1276.</a></li><li><a class="nounderline abstract_t">Oda T, Tamura K, Yoshizawa N, et al. Elevated urinary plasmin activity resistant to alpha2-antiplasmin in acute poststreptococcal glomerulonephritis. Nephrol Dial Transplant 2008; 23:2254.</a></li><li><a class="nounderline abstract_t">Cu GA, Mezzano S, Bannan JD, Zabriskie JB. Immunohistochemical and serological evidence for the role of streptococcal proteinase in acute post-streptococcal glomerulonephritis. Kidney Int 1998; 54:819.</a></li><li><a class="nounderline abstract_t">Poon-King R, Bannan J, Viteri A, et al. Identification of an extracellular plasmin binding protein from nephritogenic streptococci. J Exp Med 1993; 178:759.</a></li><li><a class="nounderline abstract_t">Batsford SR, Mezzano S, Mihatsch M, et al. Is the nephritogenic antigen in post-streptococcal glomerulonephritis pyrogenic exotoxin B (SPE B) or GAPDH? Kidney Int 2005; 68:1120.</a></li><li><a class="nounderline abstract_t">Rodriguez-Iturbe B. Autoimmunity in Acute Poststreptococcal GN: A Neglected Aspect of the Disease. J Am Soc Nephrol 2021; 32:534.</a></li><li><a class="nounderline abstract_t">Chauvet S, Berthaud R, Devriese M, et al. Anti-Factor B Antibodies and Acute Postinfectious GN in Children. J Am Soc Nephrol 2020; 31:829.</a></li><li><a class="nounderline abstract_t">Rodríguez-Iturbe B, Katiyar VN, Coello J. Neuraminidase activity and free sialic acid levels in the serum of patients with acute poststreptococcal glomerulonephritis. N Engl J Med 1981; 304:1506.</a></li><li><a class="nounderline abstract_t">Ardiles LG, Valderrama G, Moya P, Mezzano SA. Incidence and studies on antigenic specificities of antineutrophil-cytoplasmic autoantibodies (ANCA) in poststreptococcal glomerulonephritis. Clin Nephrol 1997; 47:1.</a></li><li><a class="nounderline abstract_t">Kozyro I, Korosteleva L, Chernoshej D, et al. Autoantibodies against complement C1q in acute post-streptococcal glomerulonephritis. Clin Immunol 2008; 128:409.</a></li><li><a class="nounderline abstract_t">Sorger K, Balun J, Hübner FK, et al. The garland type of acute postinfectious glomerulonephritis: morphological characteristics and follow-up studies. Clin Nephrol 1983; 20:17.</a></li><li><a class="nounderline abstract_t">Sorger K, Gessler M, Hübner FK, et al. Follow-up studies of three subtypes of acute postinfectious glomerulonephritis ascertained by renal biopsy. Clin Nephrol 1987; 27:111.</a></li><li><a class="nounderline abstract_t">Kimmelstiel P. THe hump-a lesion of glomerulonephritis. Bull Pathol 1965; 6:187.</a></li><li><a class="nounderline abstract_t">Tejani A, Ingulli E. Poststreptococcal glomerulonephritis. Current clinical and pathologic concepts. Nephron 1990; 55:1.</a></li><li><a class="nounderline abstract_t">Fries JW, Mendrick DL, Rennke HG. Determinants of immune complex-mediated glomerulonephritis. Kidney Int 1988; 34:333.</a></li><li><a class="nounderline abstract_t">Sanjad S, Tolaymat A, Whitworth J, Levin S. Acute glomerulonephritis in children: a review of 153 cases. South Med J 1977; 70:1202.</a></li><li><a class="nounderline abstract_t">Sagel I, Treser G, Ty A, et al. Occurrence and nature of glomerular lesions after group A streptococci infections in children. Ann Intern Med 1973; 79:492.</a></li><li><a class="nounderline abstract_t">Rodríguez-Iturbe B. Epidemic poststreptococcal glomerulonephritis. Kidney Int 1984; 25:129.</a></li><li><a class="nounderline abstract_t">Nissenson AR, Baraff LJ, Fine RN, Knutson DW. Poststreptococcal acute glomerulonephritis: fact and controversy. Ann Intern Med 1979; 91:76.</a></li><li><a class="nounderline abstract_t">Becquet O, Pasche J, Gatti H, et al. Acute post-streptococcal glomerulonephritis in children of French Polynesia: a 3-year retrospective study. Pediatr Nephrol 2010; 25:275.</a></li><li><a class="nounderline abstract_t">Fux CA, Bianchetti MG, Jakob SM, Remonda L. Reversible encephalopathy complicating post-streptococcal glomerulonephritis. Pediatr Infect Dis J 2006; 25:85.</a></li><li><a class="nounderline abstract_t">Orlando C, Milani GP, Simonetti GD, et al. Posterior reversible leukoencephalopathy syndrome associated with acute postinfectious glomerulonephritis: systematic review. Pediatr Nephrol 2022; 37:833.</a></li><li><a class="nounderline abstract_t">Dodge WF, Spargo BH, Travis LB. Occurrence of acute glomerulonephritis in sibling contacts of children with sporadic acute glomerulonephritis. Pediatrics 1967; 40:1028.</a></li><li><a class="nounderline abstract_t">Rodríguez-Iturbe B, Rubio L, García R. Attack rate of poststreptococcal nephritis in families. A prospective study. Lancet 1981; 1:401.</a></li><li><a class="nounderline abstract_t">Eison TM, Ault BH, Jones DP, et al. Post-streptococcal acute glomerulonephritis in children: clinical features and pathogenesis. Pediatr Nephrol 2011; 26:165.</a></li><li><a class="nounderline abstract_t">Gunasekaran K, Krishnamurthy S, Mahadevan S, et al. Clinical Characteristics and Outcome of Post-Infectious Glomerulonephritis in Children in Southern India: A Prospective Study. Indian J Pediatr 2015; 82:896.</a></li><li><a class="nounderline abstract_t">Baldwin DS, Gluck MC, Schacht RG, Gallo G. The long-term course of poststreptococcal glomerulonephritis. Ann Intern Med 1974; 80:342.</a></li><li><a class="nounderline abstract_t">Lewis EJ, Carpenter CB, Schur PH. Serum complement component levels in human glomerulonephritis. Ann Intern Med 1971; 75:555.</a></li><li><a class="nounderline abstract_t">Cameron JS, Vick RM, Ogg CS, et al. Plasma C3 and C4 concentrations in management of glomerulonephritis. Br Med J 1973; 3:668.</a></li><li><a class="nounderline abstract_t">Wyatt RJ, Forristal J, West CD, et al. Complement profiles in acute post-streptococcal glomerulonephritis. Pediatr Nephrol 1988; 2:219.</a></li><li><a class="nounderline abstract_t">Yamakami K, Yoshizawa N, Wakabayashi K, et al. The potential role for nephritis-associated plasmin receptor in acute poststreptococcal glomerulonephritis. Methods 2000; 21:185.</a></li><li><a class="nounderline abstract_t">Parra G, Rodríguez-Iturbe B, Batsford S, et al. Antibody to streptococcal zymogen in the serum of patients with acute glomerulonephritis: a multicentric study. Kidney Int 1998; 54:509.</a></li><li><a class="nounderline abstract_t">Kaplan EL, Anthony BF, Chapman SS, et al. The influence of the site of infection on the immune response to group A streptococci. J Clin Invest 1970; 49:1405.</a></li><li><a class="nounderline abstract_t">Ayoub EM, Wannamaker LW. Streptococcal antibody titers in Sydenham's chorea. Pediatrics 1966; 38:946.</a></li><li><a class="nounderline abstract_t">Pais PJ, Kump T, Greenbaum LA. Delay in diagnosis in poststreptococcal glomerulonephritis. J Pediatr 2008; 153:560.</a></li><li><a class="nounderline abstract_t">Johnston F, Carapetis J, Patel MS, et al. Evaluating the use of penicillin to control outbreaks of acute poststreptococcal glomerulonephritis. Pediatr Infect Dis J 1999; 18:327.</a></li><li><a class="nounderline abstract_t">Dillon HC Jr. Streptococcal skin infection and acute glomerulonephritis. Postgrad Med J 1970; 46:641.</a></li><li><a class="nounderline abstract_t">Roy S 3rd, Murphy WM, Arant BS Jr. Poststreptococcal crescenteric glomerulonephritis in children: comparison of quintuple therapy versus supportive care. J Pediatr 1981; 98:403.</a></li><li><a class="nounderline abstract_t">Ferrario F, Kourilsky O, Morel-Maroger L. Acute endocapillary glomerulonephritis in adults: a histologic and clinical comparison between patients with and without initial acute renal failure. Clin Nephrol 1983; 19:17.</a></li><li><a class="nounderline abstract_t">Raff A, Hebert T, Pullman J, Coco M. Crescentic post-streptococcal glomerulonephritis with nephrotic syndrome in the adult: is aggressive therapy warranted? Clin Nephrol 2005; 63:375.</a></li><li><a class="nounderline abstract_t">Törnroth T. The fate of subepithelial deposits in acute poststreptococcal glomerulonephritis. Lab Invest 1976; 35:461.</a></li><li><a class="nounderline abstract_t">Roy S 3rd, Wall HP, Etteldorf JN. Second attacks of acute glomerulonephritis. J Pediatr 1969; 75:758.</a></li><li><a class="nounderline abstract_t">Dodge WF, Spargo BH, Bass JA, Travis LB. The relationship between the clinical and pathologic features of poststreptococcal glomerulonephritis. A study of the early natural history. Medicine (Baltimore) 1968; 47:227.</a></li><li><a class="nounderline abstract_t">Watanabe T, Yoshizawa N. Recurrence of acute poststreptococcal glomerulonephritis. Pediatr Nephrol 2001; 16:598.</a></li><li><a class="nounderline abstract_t">Potter EV, Lipschultz SA, Abidh S, et al. Twelve to seventeen-year follow-up of patients with poststreptococcal acute glomerulonephritis in Trinidad. N Engl J Med 1982; 307:725.</a></li><li><a class="nounderline abstract_t">Drachman R, Aladjem M, Vardy PA. Natural history of an acute glomerulonephritis epidemic in children. An 11- to 12-year follow-up. Isr J Med Sci 1982; 18:603.</a></li><li><a class="nounderline abstract_t">Leonard CD, Nagle RB, Striker GE, et al. Acute glomerulonephritis with prolonged oliguria. An analysis of 29 cases. Ann Intern Med 1970; 73:703.</a></li><li><a class="nounderline abstract_t">Baldwin DS. Poststreptococcal glomerulonephritis. A progressive disease? Am J Med 1977; 62:1.</a></li><li><a class="nounderline abstract_t">Pinto SW, Sesso R, Vasconcelos E, et al. Follow-up of patients with epidemic poststreptococcal glomerulonephritis. Am J Kidney Dis 2001; 38:249.</a></li><li><a class="nounderline abstract_t">Baldwin DS. Chronic glomerulonephritis: nonimmunologic mechanisms of progressive glomerular damage. Kidney Int 1982; 21:109.</a></li><li><a class="nounderline abstract_t">Hoy WE, White AV, Dowling A, et al. Post-streptococcal glomerulonephritis is a strong risk factor for chronic kidney disease in later life. Kidney Int 2012; 81:1026.</a></li></ol></div><div id="topicVersionRevision">Topic 6118 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16253886" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The global burden of group A streptococcal diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18667731" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The current state of poststreptococcal glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19384327" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : An update on acute postinfectious glomerulonephritis worldwide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8001323" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Changing pattern of glomerular disease at Beijing Children's Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2088456" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Changing perspectives in children hospitalized with poststreptococcal acute glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9509437" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Frequency of renal diseases and clinical indications for renal biopsy in children (report of the Italian National Registry of Renal Biopsies in Children). Group of Renal Immunopathology of the Italian Society of Pediatric Nephrology and Group of Renal Immunopathology of the Italian Society of Nephrology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11867637" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Fluoride exposure attenuates expression of Streptococcus pyogenes virulence factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17535174" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Post-streptococcal glomerulonephritis in Sydney: a 16-year retrospective review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/482595" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Acute post-streptococcal glomerulonephritis in adults: a long-term study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4942418" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinico-pathologic correlations in acute poststreptococcal glomerulonephritis. A correlation between renal functions, morphologic damage and clinical course of 46 children with acute poststreptococcal glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10620563" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Postinfectious glomerulonephritis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13272509" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Epidemic acute nephritis: studies on etiology, natural history and prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5822578" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Attack rates of acute nephritis after type 49 streptococcal infection of the skin and of the respiratory tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31399725" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Epidemiology, pathogenesis, treatment and outcomes of infection-associated glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17342179" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pathogenesis of poststreptococcal glomerulonephritis a century after Clemens von Pirquet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15213266" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Nephritis-associated plasmin receptor and acute poststreptococcal glomerulonephritis: characterization of the antigen and associated immune response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20708459" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Localization of nephritis-associated plasmin receptor in acute poststreptococcal glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18223261" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Elevated urinary plasmin activity resistant to alpha2-antiplasmin in acute poststreptococcal glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9734606" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Immunohistochemical and serological evidence for the role of streptococcal proteinase in acute post-streptococcal glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8340765" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Identification of an extracellular plasmin binding protein from nephritogenic streptococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16105042" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Is the nephritogenic antigen in post-streptococcal glomerulonephritis pyrogenic exotoxin B (SPE B) or GAPDH?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33531351" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Autoimmunity in Acute Poststreptococcal GN: A Neglected Aspect of the Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32034108" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Anti-Factor B Antibodies and Acute Postinfectious GN in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7231488" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Neuraminidase activity and free sialic acid levels in the serum of patients with acute poststreptococcal glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9021233" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Incidence and studies on antigenic specificities of antineutrophil-cytoplasmic autoantibodies (ANCA) in poststreptococcal glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18544473" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Autoantibodies against complement C1q in acute post-streptococcal glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6883817" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The garland type of acute postinfectious glomerulonephritis: morphological characteristics and follow-up studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3552342" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Follow-up studies of three subtypes of acute postinfectious glomerulonephritis ascertained by renal biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : THe hump-a lesion of glomerulonephritis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2191230" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Poststreptococcal glomerulonephritis. Current clinical and pathologic concepts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2971836" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Determinants of immune complex-mediated glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/333598" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Acute glomerulonephritis in children: a review of 153 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4795879" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Occurrence and nature of glomerular lesions after group A streptococci infections in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6727124" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Epidemic poststreptococcal glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/380430" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Poststreptococcal acute glomerulonephritis: fact and controversy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19876655" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Acute post-streptococcal glomerulonephritis in children of French Polynesia: a 3-year retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16395114" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Reversible encephalopathy complicating post-streptococcal glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34546419" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Posterior reversible leukoencephalopathy syndrome associated with acute postinfectious glomerulonephritis: systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6080869" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Occurrence of acute glomerulonephritis in sibling contacts of children with sporadic acute glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6110037" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Attack rate of poststreptococcal nephritis in families. A prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20652330" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Post-streptococcal acute glomerulonephritis in children: clinical features and pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25893528" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Clinical Characteristics and Outcome of Post-Infectious Glomerulonephritis in Children in Southern India: A Prospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4816174" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The long-term course of poststreptococcal glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4106150" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Serum complement component levels in human glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4200478" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Plasma C3 and C4 concentrations in management of glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3153014" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Complement profiles in acute post-streptococcal glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10816380" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The potential role for nephritis-associated plasmin receptor in acute poststreptococcal glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9690217" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Antibody to streptococcal zymogen in the serum of patients with acute glomerulonephritis: a multicentric study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5432372" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The influence of the site of infection on the immune response to group A streptococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5928726" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Streptococcal antibody titers in Sydenham's chorea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18534213" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Delay in diagnosis in poststreptococcal glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10223684" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Evaluating the use of penicillin to control outbreaks of acute poststreptococcal glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4924271" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Streptococcal skin infection and acute glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7205449" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Poststreptococcal crescenteric glomerulonephritis in children: comparison of quintuple therapy versus supportive care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6339129" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Acute endocapillary glomerulonephritis in adults: a histologic and clinical comparison between patients with and without initial acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15909597" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Crescentic post-streptococcal glomerulonephritis with nephrotic syndrome in the adult: is aggressive therapy warranted?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/792564" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The fate of subepithelial deposits in acute poststreptococcal glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5347428" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Second attacks of acute glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4874819" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The relationship between the clinical and pathologic features of poststreptococcal glomerulonephritis. A study of the early natural history.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11465811" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Recurrence of acute poststreptococcal glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7110224" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Twelve to seventeen-year follow-up of patients with poststreptococcal acute glomerulonephritis in Trinidad.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7096043" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Natural history of an acute glomerulonephritis epidemic in children. An 11- to 12-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5476201" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Acute glomerulonephritis with prolonged oliguria. An analysis of 29 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/319660" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Poststreptococcal glomerulonephritis. A progressive disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11479149" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Follow-up of patients with epidemic poststreptococcal glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7077942" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Chronic glomerulonephritis: nonimmunologic mechanisms of progressive glomerular damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22297679" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Post-streptococcal glomerulonephritis is a strong risk factor for chronic kidney disease in later life.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
